Predictive value of CHADS$_2$ and CHA$_2$DS$_2$-VASc scores for coronary artery lesions and in-hospital prognosis of patients with acute ST-segment elevation myocardial infarction

Xiaoli Li, Zhen Zeng, Xinchun Yang and Hongjiang Wang*

Abstract

Objective: To evaluate the predictive value of CHADS$_2$ and CHA$_2$DS$_2$-VASc scores for coronary artery lesions and in-hospital prognosis of patients with acute ST-segment elevation myocardial infarction (STEMI).

Methods: A total of 524 patients who were diagnosed with STEMI from January 2016 to August 2017 were retrospectively reviewed. The correlation between CHADS$_2$ and CHA$_2$DS$_2$-VASc scores with the patients’ clinical data, number of coronary lesions, Gensini scores, the target vessel and hospitalization time and in-hospital adverse events (AEs) was analyzed.

Results: The number of coronary lesions in STEMI patients was mainly single and double lesions. The CHADS$_2$ and CHA$_2$DS$_2$-VASc scores were not meaningful for predicting the number of coronary lesions. However, for left main coronary artery lesion, CHADS$_2$ score was significantly increased when the number increased ($P < 0.05$), but CHA$_2$DS$_2$-VASc score showed no statistical difference ($P > 0.05$). The incidence of target lesions in STEMI patients was mainly left anterior descending coronary artery (LAD) and right coronary artery (RCA). The two scores were not meaningful for predicting target lesions ($P > 0.05$). For the severity of coronary lesions, there was positive correlation between CHADS$_2$ score with Gensini score ($P < 0.05$), but no exact correlation between CHA$_2$DS$_2$-VASc score and Gensini score ($P > 0.05$). The stratifications of CHADS$_2$ score and CHA$_2$DS$_2$-VASc score were significantly associated with hospitalization time and adverse events during hospitalization ($P < 0.05$). The high score group had longer hospitalization time and more AEs during hospitalization than the low score group and the middle group statistically ($P < 0.05$).

Conclusion: CHADS$_2$ score had a certain value to predict the severity of coronary lesion and the presence of left main coronary artery in STEMI. The CHA$_2$DS$_2$-VASc score had no predictive ability to do it. There was no significant value in predicting the number of coronary lesions and the location of the target lesions in STEMI patients. However, both scores had the predictive ability for patient hospitalization and AEs during hospitalization.
Introduction

Coronary atherosclerotic heart disease (CAHD) is one of the most serious diseases threatening human health. In recent years, the incidence rate and mortality of CAHD have increased significantly [1]. Acute myocardial infarction (AMI), especially acute ST-segment elevated myocardial infarction (STEMI), is one of the most serious CAHDs, characterized by acute outlet, rapid progression and high mortality [2]. Many studies have reported that the occurrence and development of CAHD are significantly correlated with hypertension, diabetes, hyperlipidemia, long-term smoking, age, gender and other factors [3]. Besides, when patients with CAHD combined with multiple high-risk factors are confirmed as multivessel coronary artery disease by coronary angiography, the risk of AMI is higher and the condition can be more complex [4]. If the disease can be risk stratified in the early stage and high-risk patients can be identified, more effective interferences can be applied to reduce the incidence of AMI and improve the prognosis of patients. Currently, the commonly used scoring methods for AMI include Gensini and SYNTAX scoring system according to the shape of vascular lesions [5, 6]. Moreover, the TIMI and GRACE scoring system are widely used in evaluating the prognosis [7]. However, these scoring methods have different advantages and limitations in the treatment options and prognosis guidance of patients with AMI.

The superiority of CHADS₂ and CHA₂DS₂-VASc scores in predicting the stroke risk of patients with nonvalvular atrial fibrillation have been proved [8, 9]. Although the two scales were first used in AMI patients without atrial fibrillation, investigators have focused on the utility of CHADS₂ and CHA₂DS₂-VASc scores in predicting CAHD as many variables in the two scales are closely associated with the disease [10, 11]. They have reported that CHA₂DS₂-VASc score could be a potential independent predictor of acute stent thrombosis in STEMI patients treated with primary percutaneous coronary intervention [12]. Besides, CHA₂DS₂-VASc score is an applicable risk scoring system to assess the risk of development of portal vein thrombosis in patients with prosthetic valve [13]. However, few studies analyzed the potential value of CHADS₂ and CHA₂DS₂-VASc scores in the prediction of ASTEMI. Besides, the predictive value of CHADS₂ and CHA₂DS₂-VASc scores for in-hospital prognosis deserves to be explored.

This retrospective study reviewed the clinical data of patients with ASTEMI, including general patient data, history, vital signs, biochemical indicators, echocardiography results, coronary angiography, Gensini scores, CHADS₂ and CHA₂DS₂-VASc scores. Based on these data, we aimed to evaluate the predictive value of CHADS₂ and CHA₂DS₂-VASc scores for coronary artery lesions and in-hospital prognosis in patients with acute STEMI.

Patients and methods

The eligibility criteria were as follows. The inclusion criteria included age above 18 years, STEMI rather than acute non-STEMI and consent to receipt of emergency coronary angiography. The exclusion criteria included disturbance of consciousness, blood pressure below 80/50 mmHg, heart rate below 40 beats/min, a history of hematological diseases or malignancy and a life expectancy less than 1 year, recent history of haemorrhage, being unable to tolerate aspirin or clopidogrel and other antiplatelet drugs, and acute cerebral apoplexy. According to the eligibility criteria, the records of 524 patients with a diagnosis of ASTEMI who received emergency coronary angioplasty from January 2016 to August 2017 at Beijing Chaoyang Hospital were reviewed.

The study protocol was approved by the Ethics Committee of Beijing Chaoyang Hospital and informed consent was obtained from all study subjects. All methods were carried out in accordance with relevant guidelines and regulations.

STEMI patients were given aspirin 300 mg and clopidogrel 600 mg before emergency coronary angiography. After coronary angiography and interventional therapy were performed, statins were given to each patient. According to the blood pressure, heart rate, cardiac function level, β receptor blockers, ACEI and diuretics were provided individually. Then, all subjects were evaluated by CHADS₂ and CHA₂DS₂-VASc scores [8, 9]. According to the CHADS₂ scores, patients were divided into the low group (a score of 0–1), the middle group (a score of 2–3) and the high group (a score of 4–6). Patients evaluated by CHA₂DS₂-VASc was divided into the low group (a score of 0–2 points), the middle group (a score of 3–4) and high group (a score of 5–9).

Clinical data were recorded, including age, gender, history (hypertension, hyperlipidemia, atrial fibrillation, diabetes, hyperuricemia, peripheral arteriosclerosis, cerebral apoplexy, transient ischemic attack, cardiac insufficiency and history of interventions), Killip classification grade and the outcomes of coronary angiography. Left
ventricular ejection fraction and left ventricular end-diastolic diameter by echocardiography, and biochemical parameters including B-type natriuretic peptide (BNP), low density lipoprotein cholesterol (LDL-C), and lipoprotein A (LP(a)) were recorded.

The definition of the number of angiographic lesions was described as follows. Coronary artery and major branches were evaluated by coronary angiography. A vessel with a stenosis more than 50% was defined as a lesion vessel. When the left anterior descending coronary artery (LAD) and its branch were stenosed more than 50%, it was defined as single lesion. The definition of single lesion in the right coronary artery (RCA) or the left circumflex coronary artery (LCX) were the same as the LAD. According to the number of coronary artery lesions involved, 524 patients were divided into single vessel lesions, double vessel lesions and three vessel lesions. Patients with coronary artery disease involving the left main coronary artery were not classified separately. The severity of coronary artery disease was based on the Gensini score.

**Statistical analysis**

All data were analyzed statistically using SPSS (version 23.0; IBM, Chicago, IL). Student’s t test was performed to compare continuous variables. Chi square test was performed to compare categorical variables. The mean of multiple groups was analyzed by one-way ANOVA. The LSD method was used for comparison among groups. If data were not normally distributed, rank sum test was used for comparison among groups. Pearson correlation analysis was used for correlation analysis. Statistical significance was set at P<0.05.

**Results**

The clinical data included age, gender, LVEF, LDL-C, BNP, LP(a), hypertension, hyperlipidemia, diabetes, TIA, atrial fibrillation, Killip grade and history of PCI. The correlation between CHADS2 and CHA2DS2-VASc and STEMI was analyzed. The data are detailed in Table 1 and Table 2, respectively. There was a significant difference in age, gender, hypertension, TIA, atrial fibrillation, Killip grade, LDL-C and BNP among the three groups in CHADS2 and CHA2DS2-VASc. However, there was no significant difference in LP(a), hyperlipidemia and history of PCI among the three groups by CHADS2 or CHA2DS2-VASc. Besides, there was a significant difference in LVEF had significant difference among three groups by CHADS2 but there was no difference in CHA2DS2-VASc scores.

According to coronary angiography, the number of coronary artery lesions was determined. The data are detailed in Table 3. In CHADS2 scores, there was no significant difference in the number of lesions among different groups. Meanwhile, the comparison between groups showed no significant difference. In CHA2DS2-VASc scores, there was a significant difference in the number of lesions among the different groups. The significant difference was also found between groups (the low group vs. the middle group, \( \chi^2 = 45.452, P < 0.001 \); the middle group

### Table 1 The correlation analysis of CHADS2 and clinical data in STEMI patients

| Index              | Low group (n = 205) | Middle group (n = 247) | High group (n = 72) | Z/F/\( \chi^2 \) | P      |
|--------------------|---------------------|------------------------|---------------------|-----------------|--------|
| Age                | 54.52±9.64          | 63.62±13.3             | 72.54±9.89          | 81.026          | <0.001 |
| Gender             |                     |                        |                     |                 |        |
| Female             | 23 (4.4%)           | 53 (10.1%)             | 27 (5.2%)           | 25.364          | <0.001 |
| Male               | 182 (34.7%)         | 194 (37.0%)            | 45 (8.6%)           |                 |        |
| LVEF               | 59.85±9.87          | 57.26±10.15            | 55.45±10.43         | 5.398           | 0.005  |
| LDL-C              | 3.10±0.89           | 2.94±0.94              | 2.67±1.05           | 4.33            | 0.015  |
| BNP                | 656.8 (248.1–1343.5)| 1140 (485–2501)        | 2442 (830.1–4907)   | 48.07           | <0.001 |
| LP(a)              | 14.81 (9.1–31.7)    | 15.72 (9–28.7)         | 16.04 (9.95–25.85)  | 0.173           | 0.919  |
| Hypertension       | 61 (11.6%)          | 168 (32.1%)            | 63 (12.0%)          | 103.761         | <0.001 |
| Hyperlipidemia     | 170 (32.4%)         | 211 (40.3%)            | 54 (10.3%)          | 4.826           | 0.104  |
| Diabetes           | 21 (4.0%)           | 111 (21.2%)            | 47 (9.0%)           | 97.895          | <0.001 |
| TIA                | 0 (0%)              | 10 (1.9%)              | 47 (9.0%)           | 260.627         | <0.001 |
| Atrial fibrillation| 4 (0.8%)            | 14 (2.7%)              | 8 (1.5%)            | 10.487          | 0.005  |
| Killip             |                     |                        |                     |                 |        |
| 1                  | 172 (32.8%)         | 96 (18.3%)             | 14 (2.7%)           | 172.469         | <0.001 |
| 2                  | 32 (6.1%)           | 125 (23.9%)            | 35 (6.7%)           |                 |        |
| ≥3                 | 1 (1.2%)            | 26 (5.0%)              | 23 (4.4%)           |                 |        |
| History of PCI     | 9 (1.7%)            | 9 (1.7%)               | 3 (0.6%)            | 0.367           | 0.903  |
vs. the high group, $\chi^2 = 45.986, P = 0.001$; the low group vs. the high group, $\chi^2 = 27.315, P < 0.001$).

Gensini score can evaluate the severity of coronary artery disease. The severity of coronary artery disease increases with Gensini score. With the increase of CHADS$_2$ score and CHA2DS2-VASc score, Gensini score also showed an upward trend (Table 4). There was no significant difference among all groups in both two scoring systems. When compared the subgroups, only the high group was significantly higher than the lower group in CHADS$_2$ score ($P = 0.045 < 0.05$). The other comparisons between groups showed no significant difference. (the low CHADS$_2$ score, group vs. the middle CHADS$_2$ score, group, $t = -0.694, P = 0.488$, middle group vs high group, $t = -1.073, P = 0.285$; CHA2DS2-VASc score, low group vs middle group, $t = -0.66, P = 0.51$, the low CHADS$_2$ score group vs. the high CHADS$_2$ score group, $t = -1.052, P = 0.294$, the middle CHADS$_2$ score group vs. the high CHADS$_2$ score group, $t = -0.401, P = 0.689$). Pearson correlation analysis showed a positive correlation between CHADS$_2$ score and Gensini score ($r = 0.089, P = 0.043 < 0.05$). However, there was no correlation between CHA2DS2-VASc score and Gensini score ($r = 0.060, P = 0.174 > 0.05$) (Fig. 1).

Totally 63 patients had left main coronary artery lesion. They were respectively divided into the low group, the middle group and the high group according to the evaluation criterion of CHADS$_2$ and CHA2DS2-VASc score.

### Table 2 The correlation analysis of CHA2DS2-VASc and clinical data in STEMI patients

| Index                  | Low group (n = 184) | Middle group (n = 193) | High group (n = 147) | F/$\chi^2$ | P          |
|------------------------|---------------------|------------------------|----------------------|------------|------------|
| Age 52.62±8.7          | 60.26±10.60         | 72.90±9.98             | 178.591              | <0.001     |
| Gender                 | 180.232             |                        |                      |            |
| Female 1 (1.2%)        | 19 (3.6%)           | 83 (15.8%)             |                      |            |
| Male 183 (34.9%)       | 174 (33.2%)         | 64 (12.2%)             |                      |            |
| LVEF 59.58±10.0        | 57.26±10.42         | 56.14±10.0             | 2.892                | 0.056      |
| LDL-C 3.10±0.86        | 2.93±0.92           | 2.83±1.00              | 3.038                | 0.048      |
| BNP 605.6 (219.3–1214.3) | 944.8 (381.2–1905) | 2302.7 (1019.5–4585.5) | 86.382              | <0.001     |
| LP(a) 14.6(9.1–30)     | 13.8(9.8–27.2)      | 16.9(10.5–31.9)        | 3.62i                | 0.167      |
| Hypertension 55 (10.5%) | 128 (24.4%)         | 109 (20.8%)            | 80.289               | <0.001     |
| Hyperlipidemia 153 (29.2%) | 163 (31.1%)        | 119 (22.7%)            | 0.978                | 0.645      |
| Diabetes 21 (4.0%)     | 85 (16.2%)          | 73 (13.9%)             | 68.894               | <0.001     |
| TIA 0 (0%)             | 9 (1.7%)            | 48 (9.2%)              | 109.581              | <0.001     |
| Atrial fibrillation    | 2 (0.4%)            | 9 (1.7%)               | 15 (2.86%)           | <0.001     |
| Killip 1 151 (28.8%)   | 91 (17.4%)          | 40 (7.6%)              | 138.958              | <0.001     |
| 2 30 (5.7%)            | 89 (17.0%)          | 73 (14.0%)             |                      |            |
| ≥ 3 3 (0.6%)           | 13 (2.5%)           | 34 (6.5%)              |                      |            |
| History of PCI 9 (1.7%) | 7 (1.3%)            | 5 (1.0%)               | 0.582                | 0.762      |

### Table 3 The comparison of CHADS$_2$ and CHA2DS2-VASc with number of coronary artery lesions

| Score                  | Group      | Single lesion | Double lesions | Three lesions | $\chi^2$ | P          |
|------------------------|------------|---------------|----------------|---------------|----------|------------|
| CHADS$_2$              | Lower group| 77            | 113            | 15            | 6.128    | 0.190      |
|                         | Middle group| 87            | 131            | 29            |          |            |
|                         | High group   | 19            | 42             | 11            |          |            |
| CHA2DS2-VASc            | Lower group | 71            | 102            | 11            |          |            |
|                         | Middle group | 20            | 172            | 1             | 69.88    | <0.001     |
|                         | High group   | 39            | 89             | 19            |          |            |

### Table 4 Comparison of CHADS$_2$/CHA2DS$_2$-VASc with Gensini score among different groups

| Gensini score | Low group | Middle group | High group | F        | P        |
|---------------|-----------|--------------|------------|----------|----------|
| CHADS$_2$     | 72.18±36.81 | 74.77±36.56 | 82.6±39.19 | 2.11     | 0.122    |
| CHA2DS$_2$-VASc| 72.57±37.19 | 75.17±38.76 | 77.22±34.81 | 0.654    | 0.520    |
ss mentioned above. After comparison among all sub-
groups, the outcomes showed the prevalence of left main
冠状动脉疾病增加显著与CHADS2分数的增加；然而，CHADS2-VASc分数没有显著差异（表5）。

Totally 519 patients received emergency stent implan-
tation, and the other 5 patients underwent coronary angi-
graphy. We evaluated the correlation between coronary
target vessel lesions and CHADS2 and CHA2DS2-VASc
score. The results showed no significant difference among
the different groups in both scores (Table 6).

Adverse events during hospitalization referred to death
of all causes including recurrent myocardial ischemia,
acute left heart failure, global heart failure, pulmonary
infection, renal insufficiency, hospital stay more than
30 days, cardiac arrest, ventricular tachycardia, II* type
II and III atrioventricular block, pericardial effusion,
and cardiogenic shock. Eight patients died in our study
all due to cardiogenic shock. There was a significant
difference in the incidence of adverse events among dif-
ferent groups in both CHADS2 and CHA2DS2-VASc
score. When compared each subgroup, the high group
was significantly higher than the middle group and
the low group in both CHADS2 and CHA2DS2-VASc
score (CHADS2, the high group vs. the middle group,
$\chi^2=13.874, P<0.001$; the high group vs. the low group,
$\chi^2=23.455, P<0.001$; CHA2DS2-VASc, the high group
vs. the middle group, $\chi^2=4.029, P<0.001$; the high
group vs. the low group, $\chi^2=7.414, P=0.006$). The middle
group showed no significant difference in comparison
with the low group in both scores (CHADS2, the
low group vs. the middle group, $\chi^2=3.349, P=0.067$;
CHA2DS2-VASc, the low group vs. the middle group,
$\chi^2=0.917, P=0.338$). Kruskal–Wallis test was per-
formed to compare the length of hospitalization due to
inhomogeneity of variance ($F=29.995, P<0.001$). Com-
paring the length of hospitalization among the different
groups in both CHADS2 and CHA2DS2-VASc score, the
results showed a significant difference. When the sub-
groups were compared, the length of hospitalization in
the high group was significantly longer than that of the
middle group and the low group in both CHADS2 and
CHA2DS2-VASc score (CHADS2, the high group vs.
the middle group, $P=0.002$, the high group vs. the low
group, $P<0.001$; CHA2DS2-VASc, the high group vs. the
middle group, $P<0.001$, the high group vs. the low group,
$P<0.001$). The middle group showed no significant dif-
fERENCE in the incidence of adverse events among dif-
ferent groups in both CHADS2 and CHA2DS2-VASc
score.

**Discussion**
CHADS2 and CHA2DS2-VASc scores have been de-
veloped for risk stratification of stroke in patients with non-
valvular atrial fibrillation [9]. They are convenient scoring
systems for assessing the complexity of complications.

![Fig. 1 Scatter plot of correlation analysis between CHADS2 and Gensini scores](image)
Their convenient calculation pattern makes them ideal for patients with acute coronary syndrome. Goto et al. found that CHADS2 score can be used not only to predict the risk of stroke in patients with atrial fibrillation, but also to predict the risk of out-of-hospital cardiovascular death in patients with established or high-risk atherosclerotic diseases [14]. Recently, many studies had confirmed that the two scores can predict the prognosis of patients with coronary heart disease, cerebral arteriosclerosis and cardiac insufficiency [15–17]. Therefore, CHADS2 and CHA2DS2-VASc scores may be correlated with the severity of coronary atherosclerosis.

This study is a single center retrospective study based on consecutive patients in our hospital with a definite diagnosis of "STEMI" and who had undergone emergency coronary angiography. All subjects were divided into the low group, the middle group and the high group according to CHADS2 and CHA2DS2-VASc scores, respectively. We analyzed several indexes, and the results showed that old age, male gender, hypertension, diabetes, cerebral infarction, TIA and atrial fibrillation were the high risk factors of AMI, which are consistent with previous studies. In the hierarchical score analysis, there was no significant difference in the prevalence of hyperlipidemia among the groups. However, the LDL-C of the low group was significantly higher than that of the middle group and the high group regardless of CHADS2 or CHA2DS2-VASc score. The reason for this outcome may be that the patients in the low group were younger and had fewer comorbid diseases, so were not given enough attention and appropriate treatment. On the contrary, in the middle group and the high group, the patients were older and had more complicated diseases. So, they might pay more attention to their conditions, adopting more adequate diet control and lipid lowering therapy. The increase of LDL-C was closely related to the occurrence of AMI, accounting for a higher incidence of myocardial infarction in the low group and the middle group. If the level of LDL-C was strictly controlled by diet or medication, the incidence of AMI might be reduced. Besides, LP(a) was considered a risk factor of AMI. In our study, all patients were confirmed as STEMI, this index showed no significant difference both in CHADS2 and CHA2DS2-VASc score.

According to the analysis of coronary angiography, the incidence of double vessel lesion was higher than that of single vessel lesion and three vessel lesion both in CHADS2 and CHA2DS2-VASc scores. This outcome is different from the previous study that multivessel lesion was the main coronary artery disease in STEMI. STEMI usually occurs on the basis of coronary atherosclerotic stenosis. Due to some inducements, coronary atherosclerotic plaque could rupture. After platelets gathered on the surface of the ruptured plaque and thrombi were formed. When the coronary artery lumen was blocked, it could lead to myocardial ischemia and necrosis [18, 19]. From the incidence of target vessel lesion in our study, the LAD was the most common (41.7%—51.6%), RCA was the second (35.9%—46.1%), and LCX was the lowest (10.9%—17.0%) in both CHADS2 and CHA2DS2-VASc score. There was no significant difference in the proportion of LAD, LCX and RCA in CHADS2 and CHA2DS2-VASc score. Therefore, the incidence of target vessel lesions in STEMI patients was LAD > RCA > LCX. However, this was valueless in predicting the location of target vessel lesions. As far as severe and specific left main coronary artery lesion, we found that with the increase of CHADS2 score, the prevalence of left main coronary artery disease increased significantly, which, however, was not seen with increase in CHA2DS2-VASc score. Gensini score is a quantitative measurement system for the coronary artery, and its calculation and application are relatively simple [20]. In recent years, many studies have evaluated the relationship between disease factors and the severity of coronary artery disease by studying the correlation between disease factors and Gensini score [21]. In our study, the results showed that with the increase of CHADS2 and CHA2DS2-VASc score, Gensini score showed an upward trend. Besides, there was a positive correlation between Gensini score and CHADS2 score,

| Table 7 | Comparing the adverse events/hospitalization day among different group in both CHADS2 and CHA2DS2-VASc score |
|---------|---------------------------------------------------------------|
|         | CHADS2 | CHA2DS2-VASc |
|         | Low group | Middle group | High group | Low group | Middle group | High group |
| Adverse events (male/female) | 0/0 | 3/1 | 4/4 | 1/0 | 3/0 | 3/5 |
| \( \chi^2 \) | 55.403 | <0.001 | 22.028 | <0.001 |
| \( P \) | <0.001 | <0.001 | <0.001 |
| Hospitalization day | 7.28±3.368 | 8.41±4.620 | 12.04±11.961 | 7.09±3.318 | 7.76±4.217 | 11.13±9.070 |
| \( H \) | 34.019 | <0.001 | 69.474 | <0.001 |
but no correlation was found between Gensini score and CHA2DS2-VASc score. This outcome might be due to the small sample size and two grading methods in this study.

In this study, we observed that there were significant differences in the incidence of adverse events and length of hospitalization among the subgroups. In these two scoring systems, the number of adverse events and length of hospitalization in the high group were significantly higher and longer than those in the middle group and the low group, but there was no significant difference between the middle group and the low group. The reason for this difference might be that the patients in the high group were older, had more complications, and had more serious vascular lesions, which led to the increase of the incidence of adverse events during hospitalization. In addition, prolonged hospitalization increased the pain of patients and hospitalization expenses. Jeong et al. [22] studied the prognosis of more than 20,000 patients with AMI who underwent PCI, showing that the higher the CHA2DS2-VASc score was, the higher the probability of in-hospital death in AMI was, which is consistent with the conclusion of our study.

However, this study still has some limitations. Firstly, this study is only a single center retrospective analysis, and the conclusions need to be further verified by large-scale multicenter prospective studies. Besides, the number of cases of left main coronary artery disease is small, which has a certain impact on the accuracy of the results. Moreover, we only selected the number of coronary artery lesions and Gensini score to evaluate the complexity of coronary artery lesions. More scoring system, such as SYNTAX and Leaman scoring method, can be used to predict lesion severity.

**Conclusion**

In conclusion, the CHADS2 score has a certain value to predict the severity of coronary lesion and the presence of the left main coronary artery in STEMI. The CHA2DS2-VASc score has no predictive ability to do it. There was no significant predictive ability to get the number of coronary lesions and the location of the target lesions in STEMI patients. However, both scores had the predictive ability for length of hospitalization and the incidence of adverse events during hospitalization. Furthermore, these two scores are easy to obtain and calculate, rendering them more suitable for clinical application.

**Acknowledgements**

None.

**Authors’ contributions**

XL and HW contributed to the conception and design of the study. All authors participated in the clinical practice, including diagnosis, treatment, consultation and follow up of patients. XL and ZZ contributed to the acquisition of data. ZZ and XY contributed to the analysis of data. XL wrote the manuscript. HW revised the manuscript. All authors approved the final version of the manuscript.

**Funding**

No funding was received for this study.

**Availability of data and materials**

The datasets generated and analyzed during the current study are available from the corresponding author on reasonable request.

**Declarations**

**Ethics approval and consent to participate**

The study protocol was approved by the Ethics Committee of Beijing Chaoyang Hospital. Informed consent was obtained from all the study subjects before enrollment.

**Consent for publication**

Informed consent was obtained from all the study subjects before enrollment.

**Competing interests**

The authors declare that they have no competing interests.

**Author details**

1. Department of Cardiology, Beijing Chaoyang Hospital, Capital Medical University; Heart Center and Beijing Key Laboratory of Hypertension, Beijing Chaoyang Hospital, Capital Medical University, No 8 Gongdi South Road, Chaoyang District, Beijing 100020, China. 2. Geriatric Department, Chui Yang Liu Hospital, Tsinghua University, Beijing 100022, China.

**Received:** 20 April 2021  **Accepted:** 8 September 2021

**Published online:** 15 September 2021

**References**

1. Lala A, Desai AS. The role of coronary artery disease in heart failure. Heart Fail Clin. 2014;10:353–65.
2. 6-segment elevation myocardial infarction. Nat Rev Dis Primers. 2019;5:40.
3. Faroux L, Guimaraes L, Wintzer-Wehekind J, Junquera L, Ferreira-Neto AN, Del Val D, Muntané-Carol G, Mohammadi S, Paradis JM, Rodés-Cabau J. Coronary artery disease and transcatheter aortic valve replacement: Jacc state-of-the-art review. J Am Coll Cardiol. 2019;74:362–72.
4. Fuster V, Ryden LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, Halperin JL, Kay GN, Le Huezey JY, Lowe JE, Olsson SB, Prystowsky EN, Tamargo JL, Wann LS. 2011 accf/ahf/hrs focused updates incorporated into the acc/aha/esc 2006 guidelines for the management of patients with atrial fibrillation: A report of the american college of cardiology foundation/american heart association task force on practice guidelines developed in partnership with the european society of cardiology and in collaboration with the american heart association. Am Heart J. 2012;164:547-552.e541.
5. Bundhun PK, Sookharee Y, Bholee A, Huang F: Application of the syntax score in interventional cardiology: A systematic review and meta-analysis. Medicine (Baltimore) 2017;96:e7410.
6. Roy SS, Abu Azam STM, Khalequzzaman M, Ullah M, Arifur Rahman M. Grace and timi risk scores in predicting the angiographic severity of non-st elevation acute coronary syndrome: Indian Heart J. 2018;70(Suppl 3):S250-s253.
7. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: Results from the national registry of atrial fibrillation. JAMA. 2001;285:2864–70.
8. Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation
using a novel risk factor-based approach: The euro heart survey on atrial fibrillation. Chest. 2010;137:263–72.

10. Vanek T, Kolesar M, Nejedly M, Jirmar R. Rescue peri-operative management of the patient with giant electrical storm and severe left ventricular dysfunction: Support by levosimendan and intraaortic balloon counterpulsation. Interact Cardiovasc Thorac Surg. 2008;7:648–50.

11. Verma A, Kilicaslan F, Marrouche NF, Minor S, Khan M, Wazni O, Burkhart JD, Belden WA, Cummings JE, Abdul-Karim A, Saliba W, Schweikert RA, Tchou PJ, Martin DO, Natale A. Prevalence, predictors, and mortality significance of the causative arrhythmia in patients with electrical storm. J Cardiovasc Electrophysiol. 2004;15:1265–70.

12. Tank VO, Aruğaslan E, Çınar T, Keskin M, Kaya A, Tekkesin AI. Association of the cha2ds2-vasc score with acute stent thrombosis in patients with an st elevation myocardial infarction who underwent a primary percutaneous coronary intervention. Med Princ Pract. 2013;22:115–23.

13. Çınar T, Hayroğlu M, Tank VO, Aruğaslan E, Keskin M, Uluganyan M, Öz A, Çağdaş M, Alper AT. The predictive value of the cha2ds2-vasc score in patients with mechanical mitral valve thrombosis. J Thromb Thrombolysis. 2018;45:571–7.

14. Goto S, Bhatt DL, Rother J, Alberts M, Hill MD, Ikeda Y, Uchiyama S, D’Agostino R, Ohman EM, Liu CS, Hirsh AT, Mas JL, Wilson PW, Corbalán R, Aicher F, Steg PG. Prevalence, clinical profile, and cardiovascular outcomes of atrial fibrillation patients with atherothrombosis. Am Heart J. 2008;156:855–63;863.e852.

15. Hong HJ, Kim YD, Cha MJ, Kim J, Lee DH, Lee HS, Nam CM, Nam HS, Heo JH. Early neurological outcomes according to cha2ds2 score in stroke patients with non-valvar atrial fibrillation. Eur J Neurol. 2012;19:284–90.

16. Kim YD, Cha MJ, Kim J, Lee DH, Lee HS, Nam CM, Nam HS, Heo JH. Increases in cerebral atherosclerosis according to cha2ds2 scores in patients with stroke nonvalvar atrial fibrillation. Stroke. 2011;42:930–4.

17. Kim YD, Cha MJ, Kim J, Lee DH, Lee HS, Nam CM, Nam HS, Heo JH. Ischaemic cardiovascular mortality in patients with non-valvar atrial fibrillation according to cha2ds2 score. Thromb Haemost. 2011;105:712–20.

18. Taşolar H, Çetin M, Balli M, Bayramoğlu A, Otuş Y, Türkmen S, Aktürk E. Cha2ds2-vasc-hs score in non-st elevation acute coronary syndrome patients: Assessment of coronary artery disease severity and complexity and comparison to other scoring systems in the prediction of in-hospital major adverse cardiovascular events. Anatol J Cardiol. 2016;16:742–8.

19. Uysal OK, Turkoğlu C, Duran M, Kaya MG, Sahin DY, Gur M, Cayli M. Predictive value of newly defined cha2ds2-vasc-hsf score for severity of coronary artery disease in st segment elevation myocardial infarction. Kardiol Pol. 2016;74:954–60.

20. Neumar RW, Shuster M, Callaway CW, Gent LM, Atkins DL, Bhanji F, Brooks SC, de Gaen AR, Domnino MW, Ferrer JMJ, Kleinman ME, Kronick SL, Lavonas EJ, Link MS, Mancini ME, Morrison LJ, O’Connor RE, Samson RA, Schexnayder SM, Singletary EM, Sinz EH, Travers AH, Wyckoff MH, Hazinski MF. Part 1: Executive summary. 2015 american heart association guidelines update for cardiopulmonary resuscitation and emergency cardiovascular care. Circulation. 2015;132:351–367.

21. Ryu KS, Park HW, Park SH, Shin HS, Ryu KH, Lee DG, Bashir ME, Lee JH, Kim SM, Lee SY, Bae JW, Hwang KK, Kim DW, Cho MC, Ahn YK, Jeong MH, Kim CJ, Park JS, Kim YJ, Jang YS, Kim HS, Seung KB. Comparison of clinical outcomes between culprit vessel only and multivessel percutaneous coronary intervention for st-segment elevation myocardial infarction patients with multivessel coronary diseases. Journal of geriatric cardiology . JGc. 2015;12:208–17.

22. Jeong YW, Jeong MH, Kim SS, Rhew SH, Ahn Y, Kim JH, Chae SC, Kim YJ, Hur SH, Seong IW, Hong TJ, Choi DH, Cho MC, Kim CJ, Seung KB, Chung WS, Jang YS, Cho SY, Rha SW, Bae JH, Cho JG, Park SJ. Cha2ds2-vasc scoring system as an initial method for screening high-risk patients in acute myocardial infarction. J Korean Cardiol. 2013;50:477–80.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.